What is Happening in Pain: The Next Wave of Sodium Channel Blockers
Intro At the end of May, Eli Lilly announced a $1 billion deal with Site One Therapeutics, a company developing a Nav1.8 […]
Author: Simon Vanstone
Project History VI: Asset Landscaping for Pharma BD and why your biotech website might be hindering your chances of being “spotted”
When you read the Pharma news sites and analysis on LinkedIn about drug patent cliffs, you might think pharmaceutical companies are sitting […]
Simon Says Listen to this Podcast
With the sun out and a few projects wrapping up, I have enjoyed longer dog walks and catching up on new pharmaceutical […]
Project History V: Your Competitor Doesn’t Always Look Like You; Why companies miss competitive threats hiding in plain sight.
Introduction: Spotting the Threat You Didn’t Expect This week’s article is based on a project I completed earlier this year as part […]
Simon joins panel discussion Behind the Headlines
Early this week, I joined Chris Spivey on PharmaTech.com’s Behind the Headlines to discuss several of the previous week’s significant life science […]
‘First mover’ isn’t always an advantage for new drugs
~1.5 years ago I was reading a Financial Times article (FT.com) on obesity drugs and their order to market when my critical […]
What does GSK know that Novartis doesn’t? Looking back at R&D bets
Following last week’s post on the slow activity in M&A in 2025 so far (Sivan-Consulting), we now have some activity picking up, […]
A slow start to M&A in 2025, and it doesn’t look to be changing soon…
It has been a bit of a writing hiatus as I have been in the middle of delivering a few short, intense […]
Many pharma companies have zigged… but Teva is zagging.
This post/article is worth a read for those interested in the evolution of Pharma Business models: Pharma Exec – The Teva Turnaround […]
Top pharma’s R&D expenditure, M&A, and In-licensing activity 2012-2021
This follows last week’s post (Link) on the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies, based […]